[1]
|
Sadeghi-Gandomani, H., Asgari-Tarazoj, A., Ghoncheh, M., Yousefi, S.M., Delaram, M. and Salehiniya, H. (2017) Lung Cancer in the World: The Incidence, Mortality Rate and Risk Factors. World Cancer Research Journal, 4, Article No. e911.
|
[2]
|
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.Y., et al. (2003) Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer (The IDEAL 1 Trial) [Corrected]. Journal of Clinical Oncology, 21, 2237-2246.
https://doi.org/10.1200/JCO.2003.10.038
|
[3]
|
Kris, M.G., Natale, R.B., Herbst, R.S., Lynch Jr., TJ, Prager, D., Belani, C.P., et al. (2003) Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial. JAMA, 290, 2149-2158. https://doi.org/10.1001/jama.290.16.2149
|
[4]
|
Nakamura, Y., Sano, K., Soda, H., Takatani, H., Fukuda, M., Nagashima, S., et al. (2012) Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 5, 1404-1409. https://doi.org/10.1097/JTO.0b013e3181e59a7b
|
[5]
|
Mizoguchi, K., Nakamura, Y., Sano, K., Sato, S., Ikegami, Y., Motoshima, K., et al. (2016) Pharmacokinetic Parameters of Gefitinib Predict Efficacy and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations. Cancer Chemotherapy and Pharmacology, 78, 377-382. https://doi.org/10.1007/s00280-016-3097-4
|
[6]
|
Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247.
https://doi.org/10.1016/j.ejca.2008.10.026
|
[7]
|
Ranson, M., Hammond, L.A., Ferry, D., Kris, M., Tullo, A., Murray, P.I., et al. (2002) ZD1839, a Selective Oral Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients with Solid, Malignant Tumors: Results of a Phase I Trial. Journal of Clinical Oncology, 20, 2240-2250.
https://doi.org/10.1200/JCO.2002.10.112
|
[8]
|
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D.G., et al. (2002) Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Five Selected Solid Tumor Types. Journal of Clinical Oncology, 20, 4292-4302.
https://doi.org/10.1200/JCO.2002.03.100
|
[9]
|
Herbst, R.S., Maddox, A.M., Rothenberg, M.L., Small, E.J., Rubin, E.H., Baselga, J., et al. (2002) Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non-Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial. Journal of Clinical Oncology, 20, 3815-3825. https://doi.org/10.1200/JCO.2002.03.038
|
[10]
|
Nakagawa, K., Tamura, T., Negoro, S., Kudoh, S., Yamamoto, N., Yamamoto, N., et al. (2003) Phase I Pharmacokinetic Trial of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib (‘Iressa’, ZD1839) in Japanese Patients with Solid Malignant Tumors. Annals of Oncology, 14, 922-930.
https://doi.org/10.1093/annonc/mdg250
|
[11]
|
Dahlberg, S.E., Schiller, J.H., Bonomi, P.B., Sandler, A.B., Brahmer, J.R., Ramalingam, S.S. and Johnson, D.H. (2013) Body Mass Index and Its Association with Clinical Outcomes for Advanced Non-Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials. Journal of Thoracic Oncology, 8, 1121-1127.
https://doi.org/10.1097/JTO.0b013e31829cf942
|
[12]
|
National Cancer Institute (2010) Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. U.S. Department of Health and Human Services, Washington DC.
https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
|
[13]
|
Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., et al. (2004) Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine, 350, 2129-2139. https://doi.org/10.1056/NEJMoa040938
|
[14]
|
Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., et al. (2004) EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science, 304, 1497-500.
https://doi.org/10.1126/science.1099314
|
[15]
|
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., et al. (2004) EGF Receptor Gene Mutations Are Common in Lung Cancers from “Never Smokers” and Are Associated with Sensitivity of Tumors to Gefitinib and Erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 101, 13306-13311.
https://doi.org/10.1073/pnas.0405220101
|
[16]
|
Jackman, D., Pao, W., Riely, G.J., Engelman, J.A., Kris, M.G., Janne, P.A., Lynch, T., Johnson, B.E., Miller, V.A. (2010) Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 28, 357-360. https://doi.org/10.1200/JCO.2009.24.7049
|
[17]
|
Park, K., Tan, E.H., O’Byrne, K., Zhang, L., Boyer, M., Mok, T., et al. (2016) Afatinib versus Gefitinib as First-Line Treatment of Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer (LUX-Lung 7): A Phase 2B, Open-Label, Randomised Controlled Trial. The Lancet Oncology, 17, 577-589.
https://doi.org/10.1016/S1470-2045(16)30033-X
|
[18]
|
Janjigian, Y.Y., Park, B.J., Zakowski, M.F., Ladanyi, M., Pao, W., D’Angelo, S.P., Kris, M.G., Shen, R., Zheng, J. and Azzoli, C.G. (2011) Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas That Harbor EGFR Mutations. Journal of Thoracic Oncology, 6, 569-575.
https://doi.org/10.1097/JTO.0b013e318202bffe
|
[19]
|
Wang, H., Huang, J., Yu, X., Han, S., Yan, X., Sun, S., et al. (2014) Different Efficacy of EGFR Tyrosine Kinase Inhibitors and Prognosis in Patients with Subtypes of EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. Journal of Cancer Research and Clinical Oncology, 140, 1901-1909.
https://doi.org/10.1007/s00432-014-1709-0
|
[20]
|
Kobayashi, H., Sato, K., Niioka, T., Miura, H., Ito, H. and Miura, M. (2015) Relationship among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients with Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 16, 274-281. https://doi.org/10.1016/j.cllc.2014.12.004
|
[21]
|
Zhao, Y.Y., Li, S., Zhang, Y., Zhao, H.Y., Liao, H., Guo, Y., et al. (2011) The Relationship between Drug Exposure and Clinical Outcomes of Non-Small Cell Lung Cancer Patients Treated with Gefitinib. Medical Oncology, 28, 697-702. https://doi.org/10.1007/s12032-010-9541-0
|
[22]
|
Zhang, W., Wei, Y., Yu, D., Xu, J. and Peng, J. (2018) Gefitinib Provides Similar Effectiveness and Improved Safety than Erlotinib for East Asian Populations with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. BMC Cancer, 18, Article No. 780. https://doi.org/10.1186/s12885-018-4685-y
|
[23]
|
Lu, T., Li, Q., Li, L., Yang, K., Zhou, D., Gao, J., et al. (2020) Results of EGFR Mutations Detected in Pleural Effusion and Its Clinical Significance in 132 Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study in A Single Center. Chinese Journal of Lung Cancer, 23, 1059-1065.
|
[24]
|
Hirose, T., Fujita, K., Kusumoto, S., Oki, Y., Murata, Y., Sugiyama, T., et al. (2016) Association of Pharmacokinetics and Pharmacogenomics with Safety and Efficacy of Gefitinib in Patients with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer. Lung Cancer, 93, 69-76. https://doi.org/10.1016/j.lungcan.2016.01.005
|
[25]
|
Wu, L.Y., Cheng, Y., Zhou, X., Lee, K.H., Nakagawa, K., Niho, S., et al. (2017) Dacomitinib versus Gefitinib as First-Line Treatment for Patients with EGFR-Mutation-Positive Non-Small-Cell Lung Cancer (ARCHER 1050): A Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 18, 1454-1466.
https://doi.org/10.1016/S1470-2045(17)30608-3
|
[26]
|
Okuda, Y., Sato, K., Sudo, K., Hasegawa, Y., Asano, M., Miura, H., et al. (2017) Low Plasma Concentration of Gefitinib in Patients with EGFR Exon 21 L858R Point Mutations Shortens Progression-Free Survival. Cancer Chemotherapy and Pharmacology, 79, 1013-1020. https://doi.org/10.1007/s00280-017-3285-x
|